Beyond the Randomized Clinical Trial: Citrate for Continuous Renal Replacement Therapy in Clinical Practice
|
|
- Berenice Bell
- 6 years ago
- Views:
Transcription
1 Original Paper Received: May 8, 2013 Accepted: August 23, 2013 Published online: November 19, 2013 Beyond the Randomized Clinical Trial: Citrate for Continuous Renal Replacement Therapy in Clinical Practice L. Tovey H. Dickie S. Gangi M. Terblanche C. McKenzie R. Beale D. Treacher M. Ostermann Department of Critical Care, King s College London, King s Health Partners, Guy s & St Thomas Foundation Hospital, London, UK Key Words Citrate Acute kidney injury Continuous renal replacement therapy Anticoagulation Abstract Background: Premature circuit clotting is a major problem during continuous renal replacement therapy (CRRT). Six randomized controlled trials confirmed that regional anticoagulation with citrate is superior to heparin. Our objective was to compare circuit patency with citrate, heparin and epoprostenol in routine clinical practice. Methods: We retrospectively analysed data on circuit patency of all circuits used in a single centre between September 2008 and August We differentiated between premature filter clotting, elective discontinuation and waste. Results: 309 patients were treated with CRRT (n = 2,059 circuits). The mean age was 65.7; 63.8% were male. The methods to maintain circuit patency were unfractionated heparin (42.3%), epoprostenol (23.0%), citrate (14.7%), combinations of different anticoagulants (14.6%) and no anticoagulation (4.7%). Premature clotting was the most common reason for circuit discontinuation among circuits anticoagulated with heparin, epoprostenol or combinations of different anticoagulants (59 62%). Among circuits anticoagulated with citrate the main reason for discontinuation was elective (61%). Hazard regression analysis confirmed significantly better circuit survival with citrate. Changing from heparin to citrate decreased the risk of premature circuit clotting by 75.8%. Conclusion: In routine clinical practice, regional anticoagulation with citrate is associated with significantly better circuit patency than heparin or epoprostenol S. Karger AG, Basel Introduction The practice of renal replacement therapy (RRT) of critically ill patients in the intensive care unit varies worldwide with differences in the main providers (i.e. nephrology versus critical care team, nurses versus doctors), preferred modalities and type of anticoagulation [1]. Unfractionated heparin is the most commonly used anticoagulant during continuous RRT (CRRT) mainly as a result of familiarity, low cost and ease of administration and monitoring. The obvious drawback is the risk of bleeding. An alternative is citrate which offers regional anticoagulation without systemic anticoagulation. Citrate acts by chelating calcium and therefore inhibits the clotting cascade at several levels. The principle of regional anticoagulation is based on pre-filter infusion of citrate aiming for an ionized Ca concentration [Ca i ] of <0.35 mmol/l, and calcium replacement either post-filter or via a separate line to correct for calcium losses [2]. The advantages are karger@karger.com S. Karger AG, Basel /13/ $38.00/0 Marlies Ostermann, PhD, MD, FRCP Department of Critical Care Medicine King s College London, Guy s & St Thomas Foundation Hospital London SE1 7EH (UK) gstt.nhs.uk
2 better circuit patency and fewer bleeding complications. In addition, citrate serves as a source for the production of bicarbonate. Different methods of citrate anticoagulation have been developed for continuous haemodialysis, haemofiltration and haemodiafiltration. Some protocols use a fixed dose of citrate in relation to blood flow [3]. Others measure postfilter [Ca i ] and adjust the citrate infusion accordingly, a technique which is more complicated but optimizes anticoagulation [4]. Despite the fact that two meta-analyses including six different randomized controlled trials (RCTs) concluded that regional anticoagulation with citrate was superior to heparin [4, 5], it is not standard care yet. The most common concerns relate to the complexity of the technique, the risk of serious metabolic complications, concern about citrate accumulation in patients with liver disease and potentially higher financial costs compared to heparin. It is not uncommon that the beneficial effect of a therapy is confirmed through well-conducted RCTs but its adoption into routine clinical practice is slow [6]. This is particularly relevant for complex therapies which may be effective in the controlled research setting but are difficult to implement in day-to-day practice where less experienced healthcare workers are faced with different pressures and constraints. For this reason it is important to evaluate a proven therapy and to assess its efficacy in routine clinical care. In early 2008, we were the first intensive care unit in the UK to introduce regional anticoagulation with citrate. At that time, a decision was made to limit the use of citrate to patients with either contraindications to unfractionated heparin or repeated episodes of premature filter clotting on heparin. The objective of the following analysis was to evaluate the performance of citrate anticoagulation in routine clinical practice outside the research setting by comparing circuit patency with citrate, heparin and epoprostenol anticoagulation. M e t h o d s Setting Guy s & St Thomas NHS Foundation Hospital is a tertiary care centre with 49 critical care beds where CRRT can be provided. The critical care team is responsible for the initiation and provision of RRT. CR RT P ro t o c o l In , we used continuous veno-venous haemofiltration (CVVH) and continuous veno-venous haemodialysis (CVVHD) for patients with severe acute kidney injury. Our firstline anticoagulant was unfractionated heparin which was routinely administered via the circuit, unless the patient needed systemic heparin for other medical indications. As described previously, our heparin algorithm does not have a target-activated partial thromboplastin time ratio (APTTr) but instead allows the nursing staff to adjust the dose of heparin as guided by the condition of the patient and RRT performance provided the systemic APTTr is kept 2 to prevent over-anticoagulation [7]. We performed CVVH in pre- and post-dilution mode targeting a filtration fraction <20%. If circuits clotted prematurely, the proportion of pre-dilution was gradually increased, sometimes up to 100%. Our citrate-based CRRT protocol consists of CVVHD and is based on the algorithm described by Morgera et al. [8]. The treatment is nurse-led with close supervision by specialist critical care nurses and the medical team. We use MultiFiltrate machines, Ultraflux AV1000S hemofilters (polysulfone, 1.8 m 2, cutoff 30 kda) and Ci-Ca CVVHD 1000 MultiFiltrate circuits (Fresenius Medical Care, Bad Homburg, Germany). The dialysis solution is calciumfree Ci-Ca Dialysate K2 (Na mmol/l, K mmol/l, Mg mmol/l, Cl mmol/l, HCO 3 20 mmol/l). 4% trisodium citrate and CaCl (100 mmol/l) solutions are used for citrate and CaCl 2 administration, respectively. Predefined blood flow and dialysis solution rates are prescribed according to the patient s estimated ideal body weight in a 3: 1 ratio. Infusion rates are adjusted according to post-filter and systemic [Ca i ] aiming for post-filter [Ca i ] mmol/l and systemic [Ca i ] mmol/l. In , circuits were routinely changed after 72 h if no circuit failure occurred. For patients with contraindications to heparin and citrate, we used systemic epoprostenol infusion at a rate of 5 ng/kg/min, to be increased to 10 ng/kg/min if necessary to prevent premature clotting. An a ly s i s We retrospectively analysed data on circuit patency of all circuits used during a 12-month period between September 2008 and August The type of anticoagulant and the reasons for circuit discontinuation were recorded. We differentiated between premature filter clotting, elective discontinuation (i.e. surgery, diagnostic procedures, recovery of renal function, change of line) and waste (i.e. human error, machine errors). For the statistical analysis we compared circuits anticoagulated with heparin (via circuit or systemically), citrate, epoprostenol and combinations of different anticoagulants and recorded mean values and standard deviation (SD). Heparin was used as the reference category. Proportional hazard Cox model was used to evaluate the effect of anticoagulant type on time of clotting. We modelled competing risks using a latent survivor time approach [9]. Statistical analysis was performed using Stata SE version 11.0 (STAT Corp., USA). E t h i c s The need for individual informed consent was waived because this was a retrospective analysis of data collected prospectively for routine care, and there was no breach of privacy or anonymity (UK National Research Ethics Service). R e s u l t s Between September 2008 and August 2009, 309 patients were treated with CRRT of whom 21 patients had two separate episodes of acute kidney injury where CRRT 120 Tovey/Dickie/Gangi/Terblanche/ McKenzie/Beale/Treacher/Ostermann
3 was required (n = 2,059 circuits). Their mean age was 65.7, and 63.8% were male. Different methods were used to keep the circuits patent: unfractionated heparin (42.3% of circuits), epoprostenol (23.0%), citrate (14.7%), combinations of different anticoagulants (14.6%) and no anticoagulation (4.7%). Data was missing for 12 circuits. The mean duration of circuit patency was 19.4 h (SD 17.8) with heparin, 34.7 h (SD 28.3) with citrate and 18.8 h (SD 16.0) with epoprostenol. In patients treated with unfractionated heparin via the circuit, the mean APTTr was 1.82 (SD 0.28). Premature clotting was the most common reason for circuit discontinuation among circuits anticoagulated with heparin, epoprostenol or combinations of different anticoagulants ( fig. 1 ). Among circuits anticoagulated with citrate, discontinuation was more likely to be elective (line changes, scans, etc.). A total of 108 circuits (5.2%) were discontinued for other reasons (i.e. access problems, machine failure, human error). Hazard regression analysis of the remaining 1,939 circuits showed significantly better circuit survival with citrate ( table 1 ; fig. 2 ). Changing from heparin to citrate decreased the risk of premature circuit clotting by 76.5%. There was no significant difference between heparin and epoprostenol. D i s c u s s i o n % Premature clotting Elective discontinuation Waste Heparin Epoprostenol Citrate Combination Rx Fig. 1. Reasons for circuit discontinuation. Survival Heparin 1.0 Epoprostenol Citrate 0.8 Other combinations Color version available online Several RCTs and meta-analyses have shown that citrate achieves good circuit patency and is superior to heparin [3 6, 10 15]. RCTs are regarded as the gold standard for establishing causation between a therapy and an outcome. In a well-conducted RCT, the treatment that is found to have a beneficial effect is usually considered efficacious. Yet, even when an RCT demonstrates benefit for a particular therapy, its role in routine clinical practice is not always certain and incorporation within the larger healthcare environment may be hampered by several factors, including complexity, manpower and financial constraints [6]. Our observational data demonstrate that citrate remains superior to heparin in routine clinical practice when administered and monitored by trained critical care nursing staff. In our opinion, this is an important result, especially in light of the fact that both, the Renal Association UK and the Kidney Disease Improving Global Outcomes (KDIGO) group include regional anticoagulation with citrate in their official guidelines [16, 17]. In fact, the Fig. 2. Circuit survival per anticoagulant. Table 1. Risk of premature circuit clotting AnticoagulantPredictor variable hazard rate 1 95% CI p value Heparin Citrate Epoprostenol Other Hours < <0.001 Cox proportional hazard regression. 1 Hazard rate per 1 unit change, as appropriate for each variable. Citrate for Continuous RRT in Clinical Practice 121
4 most recent KDIGO guideline recommends citrate as the first-line anticoagulant for routine CRRT [16]. Circuit patency is critical when administering CRRT. Premature filter clotting can be a major problem and result in inadequate delivery of RRT, increased blood loss, financial costs and waste of valuable nursing time. Our data confirm a significantly lower risk of filter clotting with citrate. However, as demonstrated, premature filter clotting cannot be completely avoided even with citrate. A variety of studies using different protocols found diverging circuit survival times [10 15]. In most studies, filter life was better when using citrate compared to heparin [11, 13 15] while others found no difference [10, 12]. It is obvious that the efficacy of regional anticoagulation with citrate depends on meticulous attention to detail and adherence to the protocol. Failure to achieve post-filter [Ca i ] <0.35 mmol/l will contribute to inadequate anticoagulation within the filter and premature filter clotting. Undoubtedly, the success of citrate-based anticoagulation ultimately relies on an understanding of the principles of the technique and close attention to detail. However, premature circuit clotting can occur despite optimal postfilter ionized calcium concentrations. The mechanisms are not fully understood and require further research. It is important to acknowledge some limitations of our analysis. Firstly, we report the data obtained in a single centre. It is possible that our positive experience with citrate is due to the fact that our staff were well trained before the technique was introduced in our department. However, we acknowledge that our mean filter running time of 32 h was lower compared to more recent data reported by Morgera et al. [18] who observed a median circuit survival of 61.5 h (interquartile range ) in patients treated with citrate-based CVVHD. Similarly, we observed that 34% of filters anticoagulated with citrate clotted prematurely compared to 5% in the study by Morgera et al. [18]. Although this may be related to a limited experience during the first year of us using citrate, we note that our data are better compared to results by Fealy et al. [mean circuit life with citrate 16.3 h (SD 2.4)] and similar to findings by Oudemans-van Straaten et al. [mean circuit patency 28.5 h (SD 8.8)] [4, 19, 20]. Secondly, at the time of the study period ( ), citrate was reserved for patients who either had contraindications to heparin or had had several episodes of premature circuit clotting with heparin. As a result, the groups were different. Patients treated with heparin, citrate and epoprostenol were heterogenous and varied in their comorbidity and risk of bleeding. This is also the reason why we were not able to make valid comments related to the use of blood products, metabolic complications and financial costs. Thirdly, due to limited data at the time, we did not use citrate in patients with liver disease. We are aware of recent studies showing that regional anticoagulation with citrate is possible in liver patients and our practice has changed accordingly since 2009 [21, 22]. Fourthly, our heparin algorithm only includes a maximum APTTr value but not a target value [7]. The aim of this strategy is to achieve circuit patency without unnecessary or excessive patient anticoagulation and is in line with expert opinion and current practice in the UK [23, 24]. However, we cannot exclude that circuits anticoagulated with heparin would have lasted longer if the dose of heparin had been increased. Finally, the majority of non-citrate circuits (>95%) were run in CVVH mode while patients on citrate received CVVHD. We acknowledge that this may have affected our results since haemofiltration requires higher blood flows and is associated with more hemoconcentration within the filter as a consequence of ultrafiltration [25]. In conclusion, our data confirm that citrate performs well in routine clinical practice and offers the advantage of reduced risk of clotting compared to heparin or epoprostenol. References 1 Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA: Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Intensive Care Med 2007; 33: Oudemans-van Straaten HM, Ostermann M: Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care 2012; 16: Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26: Zhang Z, Hongying N: Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012; 38: Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW: Regional citrate versus heparin anticoagulation therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 59: Nallamothu BK, Hayward RA, Bates ER: Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008; 118: Tovey/Dickie/Gangi/Terblanche/ McKenzie/Beale/Treacher/Ostermann
5 7 Ostermann M, Dickie H, Tovey L, Treacher D: Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit Care 2010; 14: Morgera S, Schneider M, Slowinski T, Vargas- Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer HH: A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37: Hougaard P: Frailty models for survival data. Lifetime Data Anal 1995; 1: Oudemans-van Straaten H: Citrate anticoagulation therapy in the critically ill. Blood Purif 2010; 29: Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation in critically ill patients. Kidney Int 2005; 67: Betjes MG, van Oosterom D, van Agteren M, van de Wetering J: Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007; 20: Morgera S, Scholle C, Voss C, Haase M, Vargas-Hein O, Krausch D, Meizer C, Rosseau S, Zuckermann-Becker H, Neumayer HH: Metabolic complications during regional citrate anticoagulation in continuous veno-venous hemodialysis: single-center experience. Nephron Clin Pract 2004; 97:c131 c Durao MS, Monte JC, Batista MC, Oliveira M, Iizuka IJ, Santos BF, Pereira VG, Cendoroglo M, Santos OF: The use of regional citrate anticoagulation in acute kidney injury. Crit Care Med 2008; 36: Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate versus heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: Clinical Practice Guidelines for Acute Kidney Injury practice_guidelines/aki.php. 17 UK Renal Association: Clinical Practice Guidelines Acute Kidney Injury. renal.org/clinical/guidelinessection/ AcuteKidneyInjury.aspx. 18 Morgera S, Schneider M, Slowinski T, Vargas- Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer HH: A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acidbase status. Crit Care Med 2009; 37: Oudemans-Van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R: A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs 2007; 30: Schultheiss C, Saugel B, Philip V, Thies P, Noe S, Mayr U, Haller B, Einwachter H, Schmid RM, Huber W: Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Critical Care 2012; 16:R Patel S, Wendon J: Regional citrate anticoagulation in patients with liver failure time for a rethink? Crit Care 2012; 16: Bellomo R, Baldwin I: Anticoagulation; in Kellum J, Bellomo R, Ronco C (eds): Continuous Renal Replacement Therapy. Oxford, Oxford University Press, 2010, pp Gatward JJ, Gibbon GJ, Wrathall G, Padkin A: Renal replacement therapy for acute renal failure: a survey of practice in adult intensive care units in the United Kingdom. Anaesthesia 2008; 63: Ricci Z, Ronco C, Bachetoni A, D Amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P: Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10:R67. Citrate for Continuous RRT in Clinical Practice 123
Sebastian Hafner 1*, Wolfgang Stahl 1, Theresa Fels 1, Karl Träger 2, Michael Georgieff 1 and Martin Wepler 1
Hafner et al. Journal of Intensive Care (2015) 3:35 DOI 10.1186/s40560-015-0102-7 RESEARCH Implementation of continuous renal replacement therapy with regional citrate anticoagulation on a surgical and
More informationJames Beck ECS 8 November 2014 Citrate anticoagulation for continuous renal replacement therapy
Citrate anticoagulation for continuous renal replacement therapy Clinical Problem A 73 year old female patient presented to the Accident and Emergency Department (A&E) with a profound anaemia, acute kidney
More informationA safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid base status*
A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid base status* Stanislao Morgera, MD; Michael Schneider, MD; Torsten Slowinski, MD; Ortrud Vargas-Hein,
More informationhigher dose with progress in technical equipment. Continuous Dialysis: Dose and Antikoagulation. prescribed and delivered
1 2 Continuous Dialysis: Dose and Antikoagulation higher dose with progress in technical equipment Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure.
More informationFabien Stucker 1, Belen Ponte 1, James Tataw 1, Pierre-Yves Martin 1, Hannah Wozniak 2, Jérome Pugin 2 and Patrick Saudan 1*
Stucker et al. Critical Care (2015) 19:91 DOI 10.1186/s13054-015-0822-z RESEARCH Open Access Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury
More informationCorrespondence should be addressed to Andreas Kortgen;
e Scientific World Journal, Article ID 808320, 7 pages http://dx.doi.org/10.1155/2014/808320 Clinical Study Anticoagulation Strategies in Venovenous Hemodialysis in Critically Ill Patients: A Five-Year
More informationCitrate Anticoagulation
Strategies for Optimizing the CRRT Circuit Citrate Anticoagulation Prof. Achim Jörres, M.D. Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum Berlin, Germany
More informationCitrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study
Intensive Care Med (2004) 30:260 265 DOI 10.1007/s00134-003-2047-x ORIGINAL Mehran Monchi Denis Berghmans Didier Ledoux Jean-Luc Canivet Bernard Dubois Pierre Damas Citrate vs. heparin for anticoagulation
More informationCRRT. Sustained low efficiency daily dialysis, SLEDD. Sustained low efficiency daily diafiltration, SLEDD-f. inflammatory cytokine IL-1 IL-6 TNF-
RRT, renal replacement therapy IHDCRRT CRRT 24 CRRT Sustained low efficiency daily dialysis, SLEDD 6 ~ 12 300 Sustained low efficiency daily diafiltration, SLEDD-f inflammatory cytokine IL-1 IL-6 TNF-
More informationAnticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD)
Hemodialysis International 2014; : Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD) Rolando CLAURE-DEL GRANADO, 1 Etienne MACEDO, 1 Sharon
More informationUNDERSTANDING THE CRRT MACHINE
UNDERSTANDING THE CRRT MACHINE Helen Dickie Renal Sister Critical Care Unit Guy s and St.Thomas NHS Foundation Trust 18.10.14 RRT options - IHD vs CRRT (1) Intermittent HaemoDialysis e.g. 4hrs daily or
More informationStefano Romagnoli, M.D., Ph.D.
CORSO CRRT Stefano Romagnoli, M.D., Ph.D. Dip. di Anestesia e Rianimazione AOU Careggi - Firenze Come mantenere la pervietà e il perfetto funzionamento del circuito. Diversi regimi di anticoagulazione.
More informationIonized Magnesium and Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy
Original Paper Received: April 21, 2015 Accepted: September 8, 2015 Published online: October 20, 2015 Ionized Magnesium and Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy Mychajlo
More informationSimplified Citrate Anticoagulation for CRRT Without Calcium Replacement
ASAIO Journal 2015 Clinical Critical Care Simplified Citrate Anticoagulation for CRRT Without Calcium Replacement Marcus Broman,* Bengt Klarin,* Karin Sandin, Ola Carlsson, Anders Wieslander, Jan Sternby,
More informationNurse-Pharmacist Collaboration in the Delivery of Continuous Renal Replacement Therapy
Cedarville University DigitalCommons@Cedarville Pharmacy Faculty Presentations School of Pharmacy 2-23-2012 Nurse-Pharmacist Collaboration in the Delivery of Continuous Renal Replacement Therapy Jeb Ballentine
More informationMetabolismo del citrato nei pazienti critici. Filippo MARIANO Dipartimento di Area Medica, SCDO di Nefrologia e Dialisi Ospedale CTO, Torino
Metabolismo del citrato nei pazienti critici Filippo MARIANO Dipartimento di Area Medica, SCDO di Nefrologia e Dialisi Ospedale CTO, Torino Regional citrate anticoagulation: the history First in hemodialysis
More informationContinuous Renal Replacement Therapy: Current Practice in Australian and New Zealand. Intensive Care Units
Continuous Renal Replacement Therapy: Current Practice in Australian and New Zealand Intensive Care Units Nigel Fealy 1,2,3, Leanne Aitken 2,4,5,6, Eugene du Toit 7, Ian Baldwin 1,3 1. Department of Intensive
More informationRegional Citrate Anticoagulation for RRTs in Critically Ill Patients with AKI
In-Depth Review Regional Citrate Anticoagulation for RRTs in Critically Ill Patients with AKI Santo Morabito,* Valentina Pistolesi,* Luigi Tritapepe, and Enrico Fiaccadori Abstract Hemorrhagic complications
More informationoxiris A single CRRT set with multiple benefits for managing critically ill patients with AKI Adsorption of inflammatory mediators
oxiris A single CRRT set with multiple benefits for managing critically ill patients with AKI Adsorption of inflammatory mediators Heparin-grafted for reduced thrombogenicity Supports renal function POWERED
More informationIntroduction. Research Article. Abstract
Research Article Experiences with Continuous Venovenous Hemofiltration using 18mmol/L predilution Citrate anticoagulation and a Phosphate Containing Replacement Solution Yuen Henry Jeffrey, Shum Hoi Ping
More informationDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
ORIGINAL ARTICLE DOI: 10.3904/kjim.2011.26.1.68 Regional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ιll Patients Undergoing Continuous Venovenous Hemodiafiltration
More informationRegional citrate anticoagulation in critically ill patients with liver and kidney failure
of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia - USA ORIGINAL ARTICLE DOI:10.5301/JN.2011.8363 Regional citrate anticoagulation in critically ill
More informationMorabito et al. BMC Nephrology 2013, 14:232
Morabito et al. BMC Nephrology 2013, 14:232 RESEARCH ARTICLE Open Access Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution:
More informationDiscrepant post filter ionized calcium concentrations by common blood gas analyzers in CRRT using regional citrate anticoagulation
Schwarzer et al. Critical Care (2015) 19:321 DOI 10.1186/s13054-015-1027-1 RESEARCH Open Access Discrepant post filter ionized calcium concentrations by common blood gas analyzers in CRRT using regional
More informationHere are the final proofs of your article. Please check the proofs carefully.
Dear Author, Here are the final proofs of your article. Please check the proofs carefully. All communications with regard to the proof should be sent to bmcproductionteam2@spi-global.com. Please note that
More informationRegional citrate anticoagulation for slow continuous ultrafiltration: risk of severe metabolic alkalosis
Clin Kidney J (2012) 5: 212 216 doi: 10.1093/ckj/sfs045 Advance Access publication 20 April 2012 Clinical Study Regional citrate anticoagulation for slow continuous ultrafiltration: risk of severe metabolic
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationContinuous renal replacement therapy (CRRT) is often used as a standard treatment for acute
Feature Continuous Renal Replacement Therapy and Anticoagulation: What Are the Options? Susan Dirkes, BSN, MSA, CCRN Rob Wonnacott, RN, MSN, CCRN Continuous renal replacement therapy is currently used
More informationFilter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables
Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables Wendy J Dunn and Shyamala Sriram Continuous renal replacement
More informationEUROANESTHESIA 2008 Copenhagen, Denmark, 31 May - 3 June RC3
RENAL REPLACEMENT THERAPY: STATE OF THE ART EUROANESTHESIA 2008 Copenhagen, Denmark, 31 May - 3 June 2008 12RC3 WILFRED DRUML Department of Medicine, Division of Nephrology Medical University of Vienna
More informationContinuous renal replacement therapy (CRRT) has grown in popularity as a
Clinical Medicine & Research Volume 13, Number 2: 89-93 2015 Marshfield Clinic Health System clinmedres.org Case Report Use of High-Flow Continuous Renal Replacement Therapy with Citrate Anticoagulation
More informationCRRT. ICU Fellowship Training Radboudumc
CRRT ICU Fellowship Training Radboudumc Timing RRT Consider the following: Underlying cause and reversibility. Rapid improvement unlikely with high dose vasopressors and continuous exposure to other risk
More informationComplications of regional citrate anticoagulation: accumulation or overload?
Schneider et al. Critical Care (2017) 21:281 DOI 10.1186/s13054-017-1880-1 VIEWPOINT Complications of regional citrate anticoagulation: accumulation or overload? Antoine G. Schneider 1,2*, Didier Journois
More informationSlowinski et al. Critical Care (2015) 19:349 DOI /s
Slowinski et al. Critical Care (2015) 19:349 DOI 10.1186/s13054-015-1066-7 RESEARCH Open Access Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence
More informationCRRT Fundamentals Pre- and Post- Test. AKI & CRRT Conference 2018
CRRT Fundamentals Pre- and Post- Test AKI & CRRT Conference 2018 Question 1 Which ONE of the following statements regarding solute clearance in CRRT is MOST correct? A. Convective and diffusive solute
More informationPaul R. Bowlin, M.D. University of Colorado Denver. May 12 th, 2008
Paul R. Bowlin, M.D. University of Colorado Denver May 12 th, 2008 Presentation Overview Background / Definitions History Indications for initiation of therapy Outcomes Studies Conclusions Questions Background
More informationContinuous renal replacement therapy. David Connor
Continuous renal replacement therapy David Connor Overview Classification of AKI Indications Principles Types of CRRT Controversies RIFL criteria Stage GFR Criteria Urine Output Criteria Risk Baseline
More informationCan We Achieve Precision Solute Control with CRRT?
Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential
More informationCRRT: QUALITY MANAGEMENT SYSTEMS
CRRT: QUALITY MANAGEMENT SYSTEMS Javier A. Neyra, MD, MSCS Director, Acute Care Nephrology & CRRT Program University of Kentucky Medical Center Disclosures and Funding Disclosures Consulting agreement
More informationRationale for renal replacement therapy in ICU: indications, approaches and outcomes. Richard Beale
Rationale for renal replacement therapy in ICU: indications, approaches and outcomes Richard Beale RIFLE classification (ADQI group) 2004 Outcome AKIN classification Definition: Abrupt (within 48 hrs)
More informationChapter 4. S.A. Nurmohamed B.P. Jallah M.G. Vervloet A. Beishuizen A.B.J. Groeneveld ASAIO J 2011; 57:48-52
Chapter 4 Pre- versus postdilution continuous venovenous hemofiltration: no effect on filter life and azotemic control in critically ill patients on heparin S.A. Nurmohamed B.P. Jallah M.G. Vervloet A.
More informationMatthew J Brain, Owen S Roodenburg, Natalie Adams, Phoebe McCracken, Lisen Hockings, Steve Musgrave, Warwick Butt and Carlos Scheinkestel.
Randomised trial of software algorithm-driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial Matthew J
More informationAccelerated Venovenous Hemofiltration: Early Technical and Clinical Experience
Accelerated Venovenous Hemofiltration: Early Technical and Clinical Experience Casey N. Gashti, MD, Susana Salcedo, MD, Virginia Robinson, RN, and Roger A. Rodby, MD Background: Renal replacement therapies
More informationC h a p t e r 8. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study
C h a p t e r 8 Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study S.A. Nurmohamed M.G. Vervloet A.R.J. Girbes P.M. ter Wee A.B.J. Groeneveld
More informationCRRT. Principles and Methods Of Anticoagulation in CRRT Ravindra L Mehta MD. FACP. Citrate Anticoagulation. Overview Practical Issues Sample Orders
Principles and Methods Of Anticoagulation in CRRT Ravindra L Mehta MD. FACP. Educational Objectives: 1. Define the goals of anticoagulation in CRRT and identify the factors which affect anticoagulant choice
More informationSt George Hospital Renal Department Guideline: INTERNAL ONLY ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS
ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS Summary Aim: To prevent clotting of the extracorporeal circuit during haemodialysis If there are no contraindications, heparin can be used. In the first
More informationCRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017
CRRT and Drug dosing Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017 This talk In scope CRRT modalities with regard to medicine Principles of drugs with regard to dialysis
More informationCRRT: The Technical Questions Modality & Dose. Ashita J. Tolwani, MD, MSc University of Alabama at Birmingham 2018
CRRT: The Technical Questions Modality & Dose Ashita J. Tolwani, MD, MSc University of Alabama at Birmingham 2018 Case A 24YOM with HTN and OSA presents with acute pancreatitis. Despite aggressive fluid
More informationMODALITIES of Renal Replacement Therapy in AKI
MODALITIES of Renal Replacement Therapy in AKI Jorge Cerdá, MD, MS, FACP, FASN Clinical Professor of Medicine Albany Medical College Albany, NY, USA cerdaj@mail.amc.edu In AKI, RRT is a multidimensional
More informationCorresponding author:
Calculating Evidence Based Renal Replacement Therapy D. Cottle, 1 S. Mousdale, 2 H. Waqar-Uddin, 3 R. Tully, 4 B. Taylor. 5 1 Consultant in Critical Care and Anaesthesia, Lancashire Teaching Hospitals
More informationChao Liu, Zhi Mao, Hongjun Kang, Jie Hu and Feihu Zhou *
Liu et al. Critical Care (2016) 20:144 DOI 10.1186/s13054-016-1299-0 RESEARCH Open Access Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients:
More informationContinuous Renal Replacement Therapy in PICU: explanation/definitions/rationale/background
Continuous Renal Replacement Therapy in PICU: explanation/definitions/rationale/background Index: 1. Introduction Pg. 1 1.1 Definitions Pg. 2 1.2 Renal replacement therapy principles Pg. 2 2. Continuous
More informationTiming, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement
Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement Prof. Dr. Achim Jörres Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
More informationRENAL FAILURE IN ICU. Jo-Ann Vosloo Department Critical Care SBAH
RENAL FAILURE IN ICU Jo-Ann Vosloo Department Critical Care SBAH DEFINITION: RIFLE criteria Criteria for initiation of RRT Modes of RRT (options) CRRT = continuous renal replacement therapy SCUF : Ultra-filtration
More informationRegional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients
Kidney International, Vol. 67 (2005), pp. 2361 2367 Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients DEMETRIOS J. KUTSOGIANNIS,R.T.NOEL
More informationA First Evaluation of OMNI, A New Device for Continuous Renal Replacement Therapy
Original Paper DOI: 1.1159/45153 Received: August 2, 216 Accepted: September 26, 216 Published online: November 16, 216 A First Evaluation of OMNI, A New Device for Continuous Renal Replacement Therapy
More informationSolute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters
Nephrol Dial Transplant (2003) 18: 961 966 DOI: 10.1093/ndt/gfg055 Original Article Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100
More informationASN Board Review: Acute Renal Replacement Therapies
ASN Board Review: Acute Renal Replacement Therapies Ashita Tolwani, M.D., M.Sc. University of Alabama at Birmingham 2014 Key issues for boards: RRT for AKI When should therapy be initiated? What are the
More informationProf Patrick Honoré,MD, PhD,FCCM Intensivist-Nephrologist
Pro-Con Debate on High Volume Hemofiltration :Burial or Ressurection? The Pro Position 1.-Why Moving From Dose To Membranes? 4.-AN69 Oxiris LPS Adsorptive Membranes in Sepsis 2.- High Cut-Off Membranes
More informationKit Assembly. Enhanced Simplicity OPERATIONAL BENEFITS. Automatic venous chamber adjustment. User friendly interface
System for CRRT Kit Assembly Enhanced Simplicity User friendly interface Flexible AcuSmart touch screen can be turned 180 degrees with up to 100 degrees of tilt in order to ensure visibility from various
More informationChapter 10: CVVH with citrate-buffered replacement solution is safe and efficacious. Abstract
Chapter 10 Continuous venovenous hemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with high bleeding risk S.A. Nurmohamed B.P. Jallah M.G. Vervloet G. Yildirim
More informationUAB CRRT Primer Ashita Tolwani, MD, MSc University of Alabama at Birmingham
UAB CRRT Primer 2018 Ashita Tolwani, MD, MSc University of Alabama at Birmingham 1 CRRT Primer Continuous Renal Replacement Therapy (CRRT) is a "catch all" term used for all the continuous modes of renal
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationContinuous renal replacement therapy: Does technique influence electrolyte and bicarbonate control?
The International Journal of Artificial Organs / Vol. 26 / no. 4, 2003 / pp. 289-296 Artificial Kidney and Dialysis Continuous renal replacement therapy: Does technique influence electrolyte and bicarbonate
More informationNO ADDED MORTALITY BENEFIT FROM CURRENT APPROACHES TO RENAL REPLACEMENT THERAPY IN ICU PATIENTS
NO ADDED MORTALITY BENEFIT FROM CURRENT APPROACHES TO RENAL REPLACEMENT THERAPY IN ICU PATIENTS *Helmut Schiffl Department of Internal Medicine IV, University Hospital Munich, Munich, Germany *Correspondence
More informationPrismaflex. Trusted. Versatile. Reliable. Making Possible Personal.
Prismaflex Trusted. Versatile. Reliable. Making Possible Personal. No two patients are the same Every patient that comes into the ICU is different, which means therapies need to be individualised to meet
More informationCan We Achieve Precision Solute Control with CRRT?
Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential
More informationRenal Replacement Therapy in Acute Renal Failure
CHAPTER 82 Renal Replacement Therapy in Acute Renal Failure R. Deshpande Introduction Acute renal failure (ARF) is defined as an abrupt decrease in renal function sufficient to result in retention of nitrogenous
More informationCRRT for the Experience User 1. Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018
CRRT for the Experience User 1 Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018 Disclosures I have no actual or potential conflict of interest
More informationTechnical aspects of RRT in AKI: access, anticoagulation, drug dosage and nutrition. Marlies Ostermann
Technical aspects of RRT in AKI: access, anticoagulation, drug dosage and nutrition Marlies Ostermann AKI guideline Chapter 3: Nutrition Chapter 5.3: Anticoagulation Chapter 5.4: Vascular access for RRT
More informationPICANet Custom Audit Definitions Renal Dataset
PICANet Custom Audit s Renal Dataset Version 1.0 (July 2016) PICANet Renal Custom Audit Data s Manual Version 1.0 July 2016 Renal Dataset Contents PICANet Custom Audit s... 1 Renal Dataset... 1 Version
More informationContinuous renal replacement therapy Gulzar Salman Amlani Aga Khan University, School of Nursing, Karachi.
Special Communication Continuous renal replacement therapy Gulzar Salman Amlani Aga Khan University, School of Nursing, Karachi. Abstract Acute renal failure refers to sudden deterioration in biochemical
More informationTechnical Considerations for Renal Replacement Therapy in Children
Technical Considerations for Renal Replacement Therapy in Children Timothy E. Bunchman, MD,* Patrick D. Brophy, MD, and Stuart L. Goldstein, MD Summary: Provision of renal replacement therapy to the critically
More informationNutrition in Acute Kidney Injury Enrico Fiaccadori
Nutrition in Acute Kidney Injury Enrico Fiaccadori Nephrology Dept. Parma University Medical School Parma, Italy Diagnosis, epidemiology and prognostic impact of proteinenergy wasting (PEW) in AKI Pathogenetic
More informationRenal Replacement Therapy in ICU. Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine
Renal Replacement Therapy in ICU Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine Introduction Need for RRT in patients with ARF is a common & increasing problem in ICUs Leading cause of ARF
More informationCommentary Recent evolution of renal replacement therapy in the critically ill patient Claudio Ronco
Commentary Recent evolution of renal replacement therapy in the critically ill patient Claudio Ronco Department of Nephrology, St Bortolo Hospital, Vicenza, Italy Corresponding author: Claudio Ronco, cronco@goldnet.it
More informationKaren Mak R.N. (Team Leader) Renal Dialysis Centre Hong Kong Sanatorium & Hospital
Karen Mak R.N. (Team Leader) Renal Dialysis Centre Hong Kong Sanatorium & Hospital - Renal Transplantation - Peritoneal Dialysis - Extracorporeal Therapy Extracorporeal Therapy It is the procedure in
More informationIntraoperative Renal Support During Liver Transplantation
LIVER TRANSPLANTATION 15:73-78, 2009 ORIGINAL ARTICLE Intraoperative Renal Support During Liver Transplantation Derek R. Townsend, 1,2 Sean M. Bagshaw, 1 Michael J. Jacka, 1,2 David Bigam, 3 Dominic Cave,
More informationLong-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction
Klingele et al. Critical Care (2017) 21:294 DOI 10.1186/s13054-017-1870-3 RESEARCH Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe
More informationDialysis Dose Prescription and Delivery. William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012
Dialysis Dose Prescription and Delivery William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012 Dose in RRT: Key concepts Dose definition Quantifying
More informationWho? Dialysis for Acute Renal Failure: Who, What, How, and When? Kathleen D. Liu, MD, PhD, MAS June 2011
Dialysis for Acute Renal Failure: Who, What, How, and When? Kathleen D. Liu, MD, PhD, MAS June 2011 Dorre Nicholau MD PhD Clinical Professor Department of Anesthesia and Perioperative Care University of
More informationPICANet Renal Dataset supplement Renal Daily Interventions
PICANet Renal Dataset supplement Renal Daily Interventions Version 2.0 (March 2017) 1 Contents PICANet Renal Dataset supplement... 1 Renal Daily Interventions... 1 Version 2.0 (March 2017)... 1 Recording
More informationCRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT
CRRT Fundamentals Pre-Test AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling at home. He
More informationTransient versus Persistent Acute Kidney Injury and the Diagnostic Performance of Fractional Excretion of Urea in Critically Ill Patients
Original Paper Received: June 27, 2013 Accepted: November 29, 2013 Published online: January 11, 2014 Transient versus Persistent Acute Kidney Injury and the Diagnostic Performance of Fractional Excretion
More informationRecent advances in CRRT
Recent advances in CRRT JAE IL SHIN, M.D., Ph.D. Department of Pediatrics, Severance Children s Hospital, Yonsei University College of Medicine, Seoul, Korea Pediatric AKI epidemiology and demographics
More informationPrecision Fluid Management in Continuous Renal Replacement Therapy
ADQI Consensus Published online: August 26, 2016 Precision Fluid Management in Continuous Renal Replacement Therapy Raghavan Murugan a Eric Hoste d, e Ravindra L. Mehta c Sara Samoni f Xiaoqiang Ding h
More informationRenal replacement therapy in Pediatric Acute Kidney Injury
Renal replacement therapy in Pediatric Acute Kidney Injury ASCIM 2014 Dr Adrian Plunkett Consultant Paediatric Intensivist Birmingham Children s Hospital, UK Aims of the presentation Important topic: AKI
More informationActive UMMC Protocols
UMMC CRRT 2018 Active UMMC Protocols 1. Standard CRRT Protocol PrismaFlex & NxStage CVVH with Fixed Ratio Regional Citrate Anticoagulation 2. No Anticoagulation Protocol PrismaFlex & NxStage CVVH with
More informationEffluent Volume in Continuous Renal Replacement Therapy Overestimates the Delivered Dose of Dialysis
Article Effluent Volume in Continuous Renal Replacement Therapy Overestimates the Delivered Dose of Dialysis Rolando Claure-Del Granado,* Etienne Macedo,* Glenn M. Chertow, Sharon Soroko,* Jonathan Himmelfarb,
More informationA novel citrate-based protocol versus heparin anticoagulation for sustained lowefficiency dialysis in the ICU: safety, efficacy, and cost
Wen et al. BMC Nephrology (2018) 19:79 https://doi.org/10.1186/s12882-018-0879-4 RESEARCH ARTICLE A novel citrate-based protocol versus heparin anticoagulation for sustained lowefficiency dialysis in the
More informationContinuous Renal Replacement Therapy in Dogs and Cats
Continuous Renal Replacement Therapy in Dogs and Cats Mark J. Acierno, MBA, DVM KEYWORDS Continuous renal replacement therapy CRRT Acute kidney injury Dialysis In the early 1900s, a young pharmacologist
More informationRegional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions
Nephrol Dial Transplant (2004) 19: 171 178 DOI: 10.1093/ndt/gfg488 Original Article Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions Olivier Cointault
More informationAcute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis
Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone
More informationEvaluation of circuit lifetime in continuous renal replacement therapy using two types of polysulfone membranes
Nakamura et al. Renal Replacement Therapy (2019) 5:1 https://doi.org/10.1186/s41100-018-0196-1 RESEARCH Open Access Evaluation of circuit lifetime in continuous renal replacement therapy using two types
More informationContinuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study
RESEARCH Open Access Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study Caroline Schultheiß *, Bernd Saugel, Veit
More informationPICANet Custom Audit Definitions Renal Dataset
PICANet Custom Audit s Renal Dataset Version 2.0 (March 2017) PICANet Renal Custom Audit Data s Manual Version 2.0 29/03/2017 Renal Dataset Contents PICANet Custom Audit s... 1 Renal Dataset... 1 Version
More informationRenal Physiology Intro to CRRT Concepts. Catherine Jones September 2017
Renal Physiology Intro to CRRT Concepts Catherine Jones September 2017 Learning Outcomes To revise anatomy & physiology of kidney in health: To understand basic principles of continuous renal replacement
More informationLarge RCT s s in RRT : What can be learnt for nursing?
Large RCT s s in RRT : What can be learnt for nursing? Ian Baldwin Dept. of Intensive Care, Austin Hospital Adjunct Professor, RMIT University CRRT 2011 Hilton Bayfront, February 22-25 SanDiego Key Hypothesis
More information7/17/2017 FSHP 2017 ANNUAL MEETING. Medication Considerations for the Adult/Pediatric ICU Patient Receiving Renal Replacement Therapy
FSHP Medication Considerations for the Adult/Pediatric ICU Patient Receiving Renal Replacement Therapy Disclosure I do not have (nor does any immediate family member have) a vested interest in or affiliation
More informationTiming, dose and mode of dialysis in acute kidney injury Zaccaria Ricci a and Claudio Ronco b,c
Timing, dose and mode of dialysis in acute kidney injury Zaccaria Ricci a and Claudio Ronco b,c a Department of Pediatric Cardiac Surgery, Bambino Gesù Children s Hospital, Rome, b Department of Nephrology,
More information